Welcome to the latest edition of our Guideline Spotlight, where we delve into the significant changes and key takeaways from the Centers for Disease Control and Prevention’s (CDC) Adult Immunization Schedule for Ages 19 Years or Older, United States, 2025. This schedule serves as a valuable tool for healthcare providers to determine the recommended vaccines for individuals within each age group. The 2025 Immunization Schedules were officially approved by the Advisory Committee on Immunization Practices (ACIP) and subsequently endorsed by the CDC Director on October 24, 2024, with publication following on November 21, 2024.

Please be aware that this summary does not cover all major points. For a comprehensive list of recommendations, please refer to the summary provided here or access the full text located here. Let’s begin!

Key Changes & Takeaways

Here are the key changes in the CDC’s Adult Vaccination Schedule for 2025:

  • COVID-19 Vaccination:
    • An additional dose of the 2024-2025 formula COVID-19 vaccine is recommended for individuals 65 years and older and for those who are moderately or severely immunocompromised, six months after their last dose.
  • Influenza Vaccination:
    • Trivalent high-dose inactivated influenza vaccine (HD-IIV3) or trivalent adjuvanted inactivated influenza vaccine (aIIV3) are now acceptable options for solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens.
  • Pneumococcal Vaccination:
    • The age for routine adult pneumococcal vaccination has been lowered from 65 to 50 years.
    • In addition, information was added for use of pneumococcal vaccines during pregnancy, and recommendations for situations when PPSV23 is unavailable.
  • Respiratory Syncytial Virus (RSV) Vaccination:
    • A single dose of RSV vaccine is recommended for adults aged 75 years and older.
    • The special situations section provides risk-based recommendations for adults aged 60-74 years, including a list of conditions that increase the risk of severe RSV disease.
  • Mpox Vaccination:
    • The Mpox note has been updated to provide clarification regarding vaccination recommendations for healthcare personnel in healthcare settings. It is important to note that vaccination for occupational risks in healthcare settings is not routinely recommended for health care personnel.
  • Meningococcal Vaccination:
    • The vaccination schedule for Bexsero has been updated in the routine vaccination and special situations sections. 
    • It is now recommended that adults at higher risk of serogroup B meningococcal disease receive a 3-dose series at 0, 1-2, and 6 months.
    • Furthermore, the guidelines for the use of MenB during pregnancy have been clarified. It is advised to delay vaccination until after pregnancy due to insufficient safety data.
  • Hepatitis B Vaccination:
    • The Special Situations section has been recently updated to provide clearer recommendations for immunocompromised individuals aged 20 years and older.
    • Additionally, the information regarding the use of hepatitis B vaccines during pregnancy has been revised to include Heplisav-B in the list of vaccine products that are safe for administration during pregnancy.
  • TDap Vaccination:
    • The routine vaccination section has been updated to clearly outline recommendations based on an individual’s vaccination history.

These updates are designed to improve protection against a range of infectious diseases and to ensure that the vaccination schedule is up-to-date with the most recent evidence and recommendations.

We greatly appreciate your review of our Guidelines Spotlight. Your thoughts and feedback are invaluable to us as we endeavor to provide informative and insightful content in our future spotlights. Thank you for being a valued member of our community.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, all rights reserved.